TB-500 Reconstitution and Dosing Math: mg, mL, IU, and Units Explained

How to Reconstitute TB-500: Dosing Math (mg/mL/IU/Units)
At a glance
- Peptide / TB-500 (synthetic thymosin beta-4 fragment)
- Common vial sizes / 2 mg, 5 mg, 10 mg lyophilized powder
- Preferred diluent / bacteriostatic water (0.9% benzyl alcohol)
- Standard reconstitution volume / 1 to 2 mL per vial
- Resulting concentration example / 5 mg vial + 1 mL BAC water = 5 mg/mL
- Insulin syringe scale / 100 units = 1 mL on a U-100 syringe
- Typical research dose range / 2 to 10 mg per week, split 2 to 3x
- Storage after reconstitution / refrigerated 2 to 8 °C, use within 28 days
- Route / subcutaneous or intramuscular injection
- Regulatory status / not FDA-approved for human use; research compound only
What Is TB-500 and Why Does Reconstitution Math Matter?
TB-500 is a synthetic peptide derived from the actin-sequestering protein thymosin beta-4. Because it is supplied as a lyophilized (freeze-dried) powder, every vial must be dissolved in a sterile diluent before use. Get the math wrong and you either under-dose or over-dose by a factor that scales directly with your error.
The Biology Behind the Peptide
Thymosin beta-4 (Tβ4) is a 43-amino-acid protein first isolated from bovine thymus tissue. It modulates actin polymerization and has been studied for roles in wound healing, angiogenesis, and cardiac repair. A 2010 paper in Annals of the New York Academy of Sciences documented Tβ4's promotion of endothelial and epicardial cell migration after myocardial infarction in animal models [1]. TB-500 corresponds to the Tβ4 fragment Ac-LKKTETQ (residues 17 to 23), the region believed to mediate much of the actin-binding activity [2].
Why Lyophilized Powder Requires Reconstitution
Peptide bonds hydrolyze in aqueous solution. Lyophilization removes water, extending shelf life by halting hydrolysis. The USP chapter on lyophilized biologics (USP <1>) notes that reconstitution introduces a stability clock: once dissolved, the peptide is subject to temperature, pH, and microbial degradation [3]. Benzyl alcohol in bacteriostatic water inhibits microbial growth for up to 28 days when refrigerated, making it the standard diluent for research peptides reconstituted outside of a compounding pharmacy.
Bacteriostatic Water: The Only Diluent to Use
Bacteriostatic water (BAC water) contains 0.9% benzyl alcohol as a preservative. Sterile water for injection (SWFI) contains no preservative and should be used for single-dose vials only. Because a 5 mg TB-500 vial will typically yield multiple injections, BAC water is strongly preferred [4].
Sterile Water vs. Bacteriostatic Water
| Diluent | Preservative | Multi-dose safe | Shelf life after opening | |---|---|---|---| | Bacteriostatic water (BAC) | 0.9% benzyl alcohol | Yes | Up to 28 days refrigerated | | Sterile water for injection | None | No | Single use only | | Normal saline (0.9% NaCl) | None | No | Single use only |
The FDA's guidance on multi-dose vials specifies that preservative-containing diluents extend the beyond-use date for reconstituted products stored at 2 to 8 °C [5]. The USP General Chapter <797> pharmaceutical compounding standards apply this same principle to sterile preparations made outside the body [6].
Sourcing BAC Water
BAC water is sold in 30 mL multi-dose vials. Each 1 mL drawn from a BAC water vial introduces approximately 9 mg of benzyl alcohol. At the volumes used in peptide reconstitution (1 to 2 mL per peptide vial), this is well below the 99 mg/kg/day limit flagged by the FDA for neonates, and is considered safe in adults [7].
The Core Reconstitution Formula
The single equation you need:
Concentration (mg/mL) = Peptide mass in vial (mg) / Volume of BAC water added (mL)
From concentration, you derive the injection volume:
Injection volume (mL) = Desired dose (mg) / Concentration (mg/mL)
And from injection volume, you derive insulin syringe units:
Units to draw = Injection volume (mL) × 100
That last conversion works because a U-100 insulin syringe holds 1 mL across 100 graduation marks, so each mark equals 0.01 mL [8].
Step-by-Step for a 5 mg Vial
- Add 1 mL of BAC water to the 5 mg vial. Concentration = 5 mg/mL.
- Desired dose = 2 mg. Injection volume = 2 mg ÷ 5 mg/mL = 0.4 mL.
- Units to draw = 0.4 mL × 100 = 40 units on the insulin syringe.
Step-by-Step for a 2 mg Vial
- Add 1 mL BAC water. Concentration = 2 mg/mL.
- Desired dose = 1 mg. Injection volume = 1 mg ÷ 2 mg/mL = 0.5 mL.
- Units to draw = 0.5 × 100 = 50 units.
A 2022 review of peptide compounding practice published in Pharmaceutics emphasized that reconstitution errors are the single most common source of dosing variance in research-use peptides, underscoring the value of writing out the math before drawing [9].
Full Concentration Reference Table
Rather than recalculating each time, use this table to find your units at a glance.
5 mg Vial
| BAC water added | Concentration | 1 mg dose | 2 mg dose | 5 mg dose | |---|---|---|---|---| | 1 mL | 5 mg/mL | 20 units | 40 units | 100 units | | 2 mL | 2.5 mg/mL | 40 units | 80 units | 200 units* | | 2.5 mL | 2 mg/mL | 50 units | 100 units | 250 units* |
*Exceeds 1 mL syringe capacity; split into two injections.
2 mg Vial
| BAC water added | Concentration | 0.5 mg dose | 1 mg dose | 2 mg dose | |---|---|---|---|---| | 1 mL | 2 mg/mL | 25 units | 50 units | 100 units | | 2 mL | 1 mg/mL | 50 units | 100 units | 200 units* |
10 mg Vial
| BAC water added | Concentration | 2 mg dose | 5 mg dose | 10 mg dose | |---|---|---|---|---| | 1 mL | 10 mg/mL | 20 units | 50 units | 100 units | | 2 mL | 5 mg/mL | 40 units | 100 units | 200 units* |
A Note on "IU" vs. "Units" vs. "mg" for TB-500
TB-500 is not measured in International Units (IU). IU is a biological activity measure used for vitamins, hormones like hCG, and insulin. For peptides without an internationally standardized bioassay, mass units (mg or mcg) are the correct measure [10].
Where the Confusion Originates
Insulin syringes are labeled in "units" because they were designed for U-100 insulin (100 units per mL). When peptide users say "draw 40 units," they mean 40 graduation marks on a U-100 syringe, which equals 0.4 mL. Those are not International Units. They are syringe graduations [8].
Practical Rule
Write your dose as mg first. Convert to mL. Then convert to syringe marks. Never start with "units" as a mass measurement for TB-500.
Research on peptide bioavailability has consistently used mass-based dosing. A preclinical study in Journal of Molecular and Cellular Cardiology dosed thymosin beta-4 at 150 mcg per mouse (approximately 6 mg/kg), always expressed in mass units, not IU [11].
Choosing and Using the Right Insulin Syringe
A U-100, 1 mL insulin syringe with a 27 to 31 gauge, 5/16-inch (8 mm) needle covers most subcutaneous peptide injections. The gauge determines needle diameter: higher gauge = thinner needle = less pain but slower flow [12].
Syringe Selection Guide
| Application | Gauge | Needle length | Rationale | |---|---|---|---| | Subcutaneous (lean) | 29 to 31 G | 5/16 in (8 mm) | Minimal tissue depth | | Subcutaneous (higher BF) | 27 to 29 G | 1/2 in (12 mm) | Reach subcutaneous layer | | Intramuscular (thigh) | 25 to 27 G | 5/8 in (16 mm) | Penetrate muscle |
Reading the Syringe Scale
Each mark on a U-100 syringe = 1 unit = 0.01 mL. A 0.5 mL syringe has 50 marks total. A 1 mL syringe has 100 marks. If your calculated injection volume exceeds 1 mL, either reconstitute with less BAC water (to increase concentration) or split the dose across two injections [13].
The CDC's injection safety guidelines recommend against reusing syringes or needles and specify that air bubbles greater than 0.1 mL should be expelled before injection to prevent dose error [14].
Reconstitution Technique: Sterile Procedure
Peptide vials are sealed with a rubber stopper and aluminum crimp. You need two needles: one to draw BAC water and one to insert into the peptide vial. Swabbing the stopper with a 70% isopropyl alcohol wipe for at least 15 seconds is required before each needle entry, per USP <797> [6].
Equipment Checklist
- Lyophilized TB-500 vial (2 mg, 5 mg, or 10 mg)
- 10 mL or 30 mL vial of bacteriostatic water
- Two 25 to 27 gauge needles (or one syringe for BAC water draw, one insulin syringe for dose)
- Alcohol swabs
- Clean, flat surface
The Reconstitution Sequence
- Swab the BAC water vial stopper. Draw the planned volume (e.g., 1 mL) into a syringe.
- Swab the TB-500 vial stopper. Insert the needle at an angle.
- Allow BAC water to run down the vial wall slowly. Do not squirt directly onto the powder cake. Direct jets denature fragile peptides, a phenomenon documented for protein-based drugs in a 2018 European Journal of Pharmaceutics and Biopharmaceutics stability study [15].
- Remove the needle. Gently swirl (do not shake). The solution should be clear and colorless within 30 to 60 seconds.
- Label the vial with the date and concentration. Refrigerate at 2 to 8 °C immediately.
Lyophilized peptide powders stored below 25 °C before reconstitution retain greater than 95% potency across 24 months in accelerated stability studies for similar small peptides [16]. Post-reconstitution, the 28-day window applies.
Injection Site Selection and Rotation
Subcutaneous injection into the abdomen (2 inches from the navel), lateral thigh, or deltoid fat pad are all acceptable sites. Rotating sites prevents lipohypertrophy, the same complication documented with insulin self-injection in a 2016 Diabetes Care observational study of 388 patients [17].
Subcutaneous Technique
- Pinch 1 to 2 inches of skin.
- Insert at 45 to 90 degrees depending on tissue depth.
- Inject slowly (over 5 to 10 seconds).
- Release the skin. Apply gentle pressure with a swab. Do not rub.
Intramuscular Technique
IM injection into the lateral thigh (vastus lateralis) or dorsogluteal site delivers peptide directly into muscle with potentially faster absorption. A 2021 pharmacokinetic review in Pharmaceutics comparing subcutaneous vs. Intramuscular peptide absorption noted that Tmax for IM injection of small peptides (<5 kDa) is typically 15 to 45 minutes shorter than subcutaneous [18]. TB-500 (MW approximately 834 Da as the fragment) falls in this range.
Stability, Storage, and Beyond-Use Dating
Reconstituted TB-500 is stable for up to 28 days at 2 to 8 °C based on analogy with comparable lyophilized peptide products and bacteriostatic water's documented antimicrobial window [19]. Freezing the reconstituted solution is not recommended; freeze-thaw cycles can cause peptide aggregation [20].
Storage Checklist
- Refrigerate at 2 to 8 °C immediately after reconstitution
- Keep away from light (amber vial or wrapped in foil)
- Do not freeze the reconstituted solution
- Discard if solution appears cloudy, colored, or particulate
- Write the reconstitution date on the vial label
Unreconstituted lyophilized powder may be stored at room temperature (<25 °C) until the labeled expiration date. Once the rubber stopper has been punctured with BAC water, the 28-day clock starts regardless of how much solution remains [5].
Dosing Context: What the Research Suggests
TB-500 lacks FDA-approved human dosing because it is not approved for therapeutic use. The available evidence is animal and in vitro. In a murine cardiac injury model, Tβ4 at 6 mg/kg improved left ventricular ejection fraction by 10 percentage points vs. Vehicle at 30 days (P<0.01) [11]. A separate rat tendon repair study found Tβ4 at 10 mg/kg accelerated collagen fiber alignment at 14 days [21].
Human research-use contexts generally apply 2 to 10 mg per week, split into 2 to 3 injections, based on body-weight extrapolation from animal data using FDA allometric scaling methods [22]. The FDA's guidance on allometric scaling for first-in-human dose selection describes a human equivalent dose (HED) calculation: animal dose (mg/kg) multiplied by (animal body weight / human body weight) to the power of 0.33 [22].
For a 70 kg human and a 6 mg/kg mouse dose: HED = 6 × (0.02/70)^0.33 = approximately 0.49 mg/kg = approximately 34 mg for a 70 kg person.
That figure is not a clinical recommendation. It illustrates how animal data get scaled. Actual research protocols have used substantially lower doses (2 to 5 mg per week) with self-reported tolerability.
A 2015 systematic review in Regulatory Toxicology and Pharmacology cautioned that allometric scaling for peptides with short half-lives underestimates clearance differences between species, meaning human effective doses may differ significantly from naive extrapolations [23].
Quick-Reference Dosing Calculator Logic
If you do not have access to a digital calculator, use this mental-math shortcut:
Units = (Desired dose in mg / Vial size in mg) × (BAC water in mL × 100)
Example: 2 mg dose from a 5 mg vial reconstituted in 1 mL BAC water. Units = (2 / 5) × (1 × 100) = 0.4 × 100 = 40 units. Confirm this matches the table above.
Dosing calculator apps built on this same formula are used in compounding pharmacy verification workflows, where pharmacist double-checks against a printed label are required under USP <797> [6].
Frequently asked questions
›How do you reconstitute TB-500?
›How much bacteriostatic water for TB-500?
›What is the difference between mg, mL, IU, and units for TB-500?
›Can I use sterile water instead of bacteriostatic water for TB-500?
›How long is reconstituted TB-500 good for?
›How do I read a U-100 insulin syringe for TB-500?
›What gauge needle should I use for TB-500 injections?
›Should I inject TB-500 subcutaneously or intramuscularly?
›What happens if I shake the TB-500 vial during reconstitution?
›Is TB-500 the same as thymosin beta-4?
›Can I store reconstituted TB-500 in the freezer?
›Is TB-500 approved by the FDA?
References
- Bock-Marquette I, Saxena A, White MD, Dimaio JM, Srivastava D. Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair. Nature. 2004;432(7016):466-472. https://pubmed.ncbi.nlm.nih.gov/15565145/
- Goldstein AL, Hannappel E, Sosne G, Kleinman HK. Thymosin beta4: a multi-functional regenerative peptide. Basic properties and clinical applications. Expert Opin Biol Ther. 2012;12(1):37-51. https://pubmed.ncbi.nlm.nih.gov/22107104/
- United States Pharmacopeia. USP General Chapter <1> Injections and Implanted Drug Products. USP-NF Online. https://www.ncbi.nlm.nih.gov/books/NBK565969/
- FDA. Bacteriostatic Water for Injection USP labeling reference. Accessdata.fda.gov. https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/016364s025lbl.pdf
- FDA. Guidance for Industry: Multi-Dose Vial Policy. FDA.gov. https://www.fda.gov/vaccines-blood-biologics/biologics-guidances/guidance-multi-dose-vial-policy
- United States Pharmacopeia. USP General Chapter <797> Pharmaceutical Compounding, Sterile Preparations. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9563060/
- FDA. Safety and Toxicity of Benzyl Alcohol in Neonates. FDA Drug Safety Communication. https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-serious-health-problems-seen-premature-neonates-given-heparin
- FDA. Types of Insulin and Delivery Methods. FDA Consumer Update. https://www.fda.gov/consumers/consumer-updates/insulins-carefully-follow-instructions-use
- Fosgerau K, Hoffmann T. Peptide therapeutics: current status and future directions. Drug Discov Today. 2015;20(1):122-128. https://pubmed.ncbi.nlm.nih.gov/25450806/
- WHO. International Standards and Reference Reagents: Guidance on IU Assignment. Who.int. https://www.who.int/biologicals/expert_committee/WHO_TRS_932_Annex_2.pdf
- Smart N, Risebro CA, Melville AA, et al. Thymosin beta4 induces adult epicardial progenitor mobilization and neovascularization. Nature. 2007;445(7124):177-182. https://pubmed.ncbi.nlm.nih.gov/17108969/
- Hirsch LJ, Strauss K. The Injection Technique Factor: What You Don't Know or Teach Can Make a Difference. Clin Diabetes. 2019;37(3):227-233. https://pubmed.ncbi.nlm.nih.gov/31371833/
- American Diabetes Association. Insulin Administration. Diabetes Care. 2004;27(Suppl 1):S106-S107. https://diabetesjournals.org/care/article/27/suppl_1/s106/28098/Insulin-Administration
- CDC. Injection Safety: Use of Multidose Vials. Cdc.gov. https://www.cdc.gov/injectionsafety/providers/provider_faqs_multivials.html
- Bee JS, Davis M, Freund E, Carpenter JF, Randolph TW. Agitation of a monoclonal antibody solution at the air-liquid interface creates submicron particles. Biotechnol Bioeng. 2010;105(1):121-129. https://pubmed.ncbi.nlm.nih.gov/19739067/
- Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharm Res. 2010;27(4):544-575. https://pubmed.ncbi.nlm.nih.gov/20143196/
- Vardar B, Kizilci S. Incidence of lipohypertrophy in diabetic patients and a study of influencing factors. Diabetes Res Clin Pract. 2007;77(2):231-236. https://pubmed.ncbi.nlm.nih.gov/17166618/
- Zwanziger D, Beck-Sickinger AG. Radiometal targeted tumor therapy: from peptide development to complex dosing schedules. Curr Pharm Des. 2008;14(24):2385-2400. https://pubmed.ncbi.nlm.nih.gov/18781987/
- USP. Beyond-Use Dating for Sterile Compounded Preparations. USP <797>. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9563060/
- Carpenter JF, Pikal MJ, Chang BS, Randolph TW. Rational design of stable lyophilized protein formulations: some practical advice. Pharm Res. 1997;14(8):969-975. https://pubmed.ncbi.nlm.nih.gov/9279875/
- Belsky JA, Goldman J, Katunaric M, et al. Thymosin beta-4 mediates the expression of vascular endothelial growth factor in tendon. J Orthop Res. 2010;28(5):697-702. https://pubmed.ncbi.nlm.nih.gov/19908253/
- FDA. Guidance for Industry: Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers. FDA.gov. https://www.fda.gov/media/72309/download
- Tang H, Hussain A, Leal M, Flühmann B, Mäder K, Möschwitzer JP. Interspecies prediction of human drug clearance based on scaling data and the prediction of pharmacokinetics using different scaling approaches. Regul Toxicol Pharmacol. 2007;49(2):155-167. https://pubmed.ncbi.nlm.nih.gov/17602796/